Dude, not everyone is a short. Take the tin foil hat

New Post Public Reply Private Reply Replies (1) Message Board
jamming1092 Riztheinvestor #56732
759
Dude, not everyone is a short. Take the tin foil hat off.

It's just hard to work out with this company who is and who is out. The product science is amazing. Dr BP and Dr JL - their work speaks for itself.

The issue is the CEO has messed up com's so much and his behavior on the CC was so bad to an investor or potential investor (who could have been with a fund ? I don't know) who knows what goes down.

On several communications the CEO is saying - "yeah, it will be not a problem. If not EUA, then it will be a request for a P3, but we strongly believe an EUA and maybe p4 at the worse."

His best marketing was us. Spreading the word, and lets be honest here - we were free and he sort of burnt some of our good will (more for some than others).

Who knows what to believe. Seriously.

And I want this product to come to market. Why - here is the rub - everyone in the world will have to get this virus. It's like the cold and or the flu now - we are going to live with it for ages. You will get it ether via contact or via a modified version (ie. vaccine). But you will get it - thats how you build anitbodies (unless we are doing DNA alteration... don't rush any of that).

Let that sink in.

So this is serious. And if we don't have a drug like this (and others) its not only the virus to worry about - other risks kick in - mass poverty and other social changes have high chance of being among them. This will cause social change (some good / some bad) as commerce adapts. But that change will effect people - usually initially those that are least equipped to handle it - because they don't have the $.

I am not thinking about my investment - its not small but if I loose some I can handle it. I hope i don't , but such is life.

I am concerned about success because it means more than a $ here or there. So yeah, as Dr JL said - this drug is a gift from God. I don't care if NP stays or goes that much - but I hope he learns and goes for a better team. It doesn't matter what NP thinks about his team - they could be good. Make it better, because others now need to believe it's a better team.

One thing you release about Biotech that is unlike bringing a product to market in other industries - its actually 3 markets :
1) hospitals and the like - you have to sell to them to get them run studies
2) The FDA - you have to convince them to grant you access to 3)
3) the real TAM (total addressable market) - distributors, partnership deals, sick people, people sick people go to etc.

We are stuck between 1 and 2 now. NP is entrepreneur - they are good at shaking things up , raising funds and disrupting a market. He has had some success getting the rolling BLA etc. Hopefully he gets some more. But hope is not a strategy. What worked in the past may not work now, as this is a new game.

You can't disrupt 3) until you are successful in 1) and 2). You can't disrupt 2). In fact, i would say if anything Covid has disrupted 2) for you about as much as you are going to get. For the sake of the product and all of us who may need this sooner or later (because we will in some form all get this virus) get people that have done this more than once (in addition to your team) . They have a record of 2). And you are going to need cash. So when you see $100M in shares for compensation (25M shares at $4) and the same management seem to point to cash flow as why they can't get things done - something needs to change. Thats it - not sell your shares, or run away - you voice for change.

Because this may be our best chance of helping the world. If what Dr JL says in that podcast is true (and I believe him) then also believe him on his other quote - put the patient first and the rest takes care of itself. In this case, that starts with the trial design and knowing how to pass the FDA requirements. That is the question people are waiting on. That needs a team of experienced people (in addition to what they have now). At the moment we hear a lot about the operational side of this business ie. inventory etc - thats great. Get the FDA - treat it like a market you need a custom marketing team.

I don't believe all the BS about the shares either (they will need shares in some form to get good people, but how you do it is key). I know what you can do with those packages. For example - an RSU is a promise to give you shares, if something happens. There are usually at least 2 things that have to happen before the shares you may have vested become real, but sometimes more. They don't just become real - they are a promise to be real if xyz happens.

You could say issue the RSU's in 2 parts - a small part that can vest now of the OTC , but you can also restrict the promise to say only materialize for a specified liquidity event ie. say buy out or up-listing with a sustained SP for X months. ie. you can control you exposure if you don't have the cash for it now and still offer incentives. Options can also be structured similarly. They are not a gift. They are incentives and rewards. There are ways to do this that can let you use the $ for growing the business offer incentives and if done right put people beyond suspicion for greedy behavior etc.

Also go hard on the BLA etc.



CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Faces Heat: Channel Stuffing Allegations Arise

Updated Category News Views 7

Gildan's Stocks Take a Dive Amid Allegations Just when you thought the market swings were calming down, Gildan Activewear Inc. (NYSE: GIL) lands in hot water, sending investors scrambling. The spotlight's on them, thanks to some eye-catching accusations from Jehoshaphat Research. The word on the street is Gildan's been engaging in some questionable financial gymnastics...

Continue Reading
iReprogram and U-M Join Forces to Combat Diabetes

Updated Category News Views 1

Diabetes: A New Frontier in Disease Management Here we go, folks. Imagine a universe where diabetes isn't just controlled but potentially reversed at the cellular level. That's the bold vision taking shape in Ann Arbor, Michigan. A new partnership between iReprogram and the University of Michigan (U-M) sets the stage for a seismic shift in how we tackle diabetes,...

Continue Reading
From Samhain to Spooktacular: Ireland's Halloween Origins

Updated Category News Views 0

Tracing Halloween's Roots: A Journey to Ireland The chill in the air can only mean one thing—Halloween is creeping up on us. But amid all the plastic pumpkins and supermarket candy, have you ever stopped to wonder where it all began? Well, folks, lace up your boots because Ireland is calling, and it's got more than a pot of gold at the end of this rainbow. No, the real...

Continue Reading
Microencapsulation Market to Hit $24B by 2031

Updated Category News Views 2

Think about wrapping a tiny gift inside a bubble that's not only protective but also dissolves at just the right moment. That, my friends, is microencapsulation summed up—and it's becoming a big deal. With the market poised to jump from $16.90 billion in 2026 to a whopping $24.02 billion by 2031, at a steady clip of 7.3% annually, there's a lot for investors to chew on...

Continue Reading
Fosun Drives Global Growth of China's Drug Innovations

Updated Category News Views 4

A New Phase for Chinese Pharmaceuticals There's a shift in the pharma world, with Fosun International leading the charge. Chinese innovative drugs are stepping onto the global stage, thanks to efforts like those of Chen Qiyu, Co-CEO of Fosun. At the Sustainability Global Leaders Conference 2026, he spoke about transforming Chinese market players into worldwide...

Continue Reading
Tower Crane Rental Market: Growth Predicted by 2031

Updated Category News Views 0

Leaning Upward: The Crane Rental Surge Ever wonder why folks are keeping a tight grip on crane rentals? Well, that's because this heavyweight industry isn't just lifting steel; it's lifting market potential. According to MarketsandMarkets™, the global tower crane rental market is set to balloon from a cool $17.99 billion in 2026 to a whopping $23.19 billion by 2031,...

Continue Reading
Alaska Air Group's Q3: Facing Headwinds and Strategies

Updated Category News Views 6

Weathering the Q3 Storm Alaska Air Group's third quarter results are in the bag, and let me tell ya, it's a mixed bag of sour lemons and hopeful limes. Reporting a net loss of $147 million or ($1.32) per share ain't the kind of results that plaster smiles on investors' faces. But hey, it's a volatile sector if there ever was one, especially with fuel costs ballooning to a...

Continue Reading
AI Traffic Sensing By AglaiaSense and Leopard Imaging

Updated Category News Views 7

Revolutionizing Traffic Sensing with Privacy The buzz in Barcelona this November is all about AglaiaSense and Leopard Imaging teaming up at the Smart City Expo World Congress. They're not just hitting exhibit after exhibit. These two are set to roll out their cutting-edge AI traffic sensing tech, and from what I'm hearing, it's miles ahead of anything we've seen before....

Continue Reading
Life After Debt: Freedom, Confidence, and Wellbeing

Updated Category News Views 12

The Unseen Upside of Financial Freedom Debt can feel like a ball and chain, dragging down everything from your sleep to your relationships. But shred that debt, and suddenly the world looks different. Accredited Debt Relief's recent survey of 1,000 folks who've paid off at least $5,000 in unsecured debt uncovers the remarkable transformations that follow. According to 93%...

Continue Reading
Samsung & NVIDIA Partner to Boost AI Supply Chain

Updated Category News Views 0

Making Moves in Semiconductor Supply Picture this: two giants locking arms to tackle the AI revolution head-on. Samsung Electro-Mechanics and NVIDIA have struck a strategic pact set to shake up the semiconductor supply chain. With a multi-year supply deal kicking off in 2026, this is no garden-variety handshake. Investment in Facilities: Bigger Fish to Fry As part of this...

Continue Reading

Top 5 Most Recently Viewed Articles

DeFi Development Corp. Teams Up with AllDomains for Growth

Updated Category News Views 94

Exciting Partnership Announcement Between DeFi Development Corp. and AllDomains Labs DeFi Development Corp. (NASDAQ: DFDV) has recently made headlines with a significant announcement regarding a new collaboration with AllDomains Labs. This partnership aims to bolster operations within the Solana ecosystem by establishing a top-notch validator while enhancing community...

Continue Reading
Innovative Measurement Solutions Unveiled at ZEISS Event

Updated Category News Views 190

Transforming Manufacturing Challenges into Opportunities ZEISS Industry Tech Days is an exciting event series that gathers manufacturers from various sectors to explore how cutting-edge metrology solutions can revolutionize processes and foster sustainable innovation. Event Overview These Tech Days will take place across several states, bringing together industry leaders...

Continue Reading
Scenthound Joins Forces with VMG for Enhanced Dog Wellness Growth

Updated Category News Views 319

Scenthound Partners with VMG for Enhanced Dog Wellness Growth In a significant move within the pet care industry, Scenthound, a prominent dog wellness franchise, has announced a strategic partnership with VMG Partners, a well-renowned growth equity firm boasting a legacy of aiding iconic consumer brands in their expansion efforts. This collaboration stands as a vital...

Continue Reading
Investing Insights: Morningstar's Stock Journey Over 20 Years

Updated Category News Views 195

Understanding Morningstar's Long-Term Investment Potential Morningstar (NASDAQ: MORN) has consistently shown its resilience and growth in the stock market over the past two decades. With an impressive annual market outperformance of 20.19%, it has cultivated an average annual return of 29.23%. Currently, the company's market capitalization stands at an extraordinary $9.76...

Continue Reading
Exploring the Ten-Year Investment Journey with KB Home

Updated Category News Views 133

Understanding KB Home's Ten-Year Growth Investing can often seem overwhelming, especially when trying to determine the best opportunities. Take KB Home (NYSE: KBH), for instance. Over the last decade, KB Home has managed to outperform the market with an impressive average annual return of 16.81%. This growth is something that any investor would appreciate, showcasing not...

Continue Reading